CD4-Targeted IL-15 Molecules and Methods of Use Patent Application
Summary
USPTO published patent application US20260109746A1 for CD4-targeted IL-15 variant molecules and methods of use, filed October 21, 2025 (Application No. 19364662). The application names twelve inventors and covers CPC classifications including C07K 14/5443, A61K 47/6813, and A61P 35/00, indicating therapeutic applications in cancer and antiviral treatments. The application remains in draft stage and has not yet been granted.
“Provided are CD4-targeted IL-15 variant molecules and methods for use.”
About this source
USPTO classification C07K covers peptides: short amino-acid chains that form the backbone of antibodies, hormones, vaccines, and increasingly a wider class of therapeutic modalities. Every newly published application in C07K lands in this feed, around 175 a month. Applications publish 18 months after filing, so this feed reveals what antibody engineering groups, vaccine developers, and plant biotech researchers were working on in the prior year and a half. Watch this if you compete in biologics, file freedom-to-operate analyses on antibody drug candidates, scout acquisition targets in vaccine platforms, or track protein-based agricultural biotech filings.
What changed
USPTO published patent application US20260109746A1 for CD4-targeted IL-15 variant molecules and associated methods of use. The application was filed on October 21, 2025, under Application No. 19364662, and names twelve inventors. CPC classifications (C07K 14/5443, A61K 47/6813, A61P 35/00) indicate therapeutic applications in cancer and antiviral treatments. The patent application remains in draft stage and has not yet been examined or granted.
Affected parties include pharmaceutical and biotechnology companies engaged in IL-15-related research or immunotherapy development. Competitors in the CD4-targeted cytokine space should monitor this application for potential freedom-to-operate considerations. The application provides early visibility into the claiming strategy and therapeutic indications being pursued by the applicant.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CD4-TARGETED IL-15 MOLECULES AND METHODS OF USE
Application US20260109746A1 Kind: A1 Apr 23, 2026
Inventors
Manuel Baca, Magdeleine S. Hung, Alivelu M. Irrinki, Bo Jiang, Jasmine Kaur, Daniel Keri, Chingwei V. Lee, Prasenjit K. Mukherjee, Jeffrey P. Murry, Baljinder S. Randhawa, Majlinda K. Thomas, Hector Viadiu-Ilarraza
Abstract
Provided are CD4-targeted IL-15 variant molecules and methods for use.
CPC Classifications
C07K 14/5443 A61K 47/6813 A61K 47/6849 A61P 31/18 A61P 35/00 C07K 14/7155 C07K 16/2812 A61K 38/00 C07K 2317/52 C07K 2317/565 C07K 2319/30
Filing Date
2025-10-21
Application No.
19364662
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.